The Effect of¹³¹I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

“…Some patients will have a reduction in tumor burden with additional treatments that may offer a survival or palliative benefit (204,(210)(211)(212).…”

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy

“…In radioiodine therapy of metastatic thyroid cancer, the therapeutic activity was chosen to deliver the MTAD of 2 Gy to the red marrow. This approach was implemented more than 50 years ago by Benua et al [1], and was successfully applied in the following decades by Leeper [2]. Unfortunately, the method has now been abandoned by many institutions, but it has continued in use in other centres [3][4][5][6][7][8].…”

Controversies in the follow-up and management of well-differentiated thyroid cancer.

“…Whole-body dosimetry calculates the maximal dose of radioiodine that will deliver less than toxic radiation levels to bone marrow and lungs, while lesional dosimetry calculates the dose of radioiodine required to deliver a lethal amount of radiation to a specific tumor mass (see below). Wholebody dosimetry, as described by Berman et al (1968) and Leeper (1973), has become routine at some institutions in the USA and Europe. Dosimetry calculations require measurement of the rate of radiation clearance from patients following administration of the scanning dose of I-131 prior to therapy (Van Nostrand et al 2002).…”